Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Retinitis pigmentosa 1 protein (RP1) is a photoreceptor-specific, microtubule-associated protein encoded by the RP1 gene, a member of the doublecortin family[1][5][6]. It binds microtubules through its N-terminal doublecortin domains, regulating microtubule polymerization and stabilizing the axoneme structure of photoreceptor cells in the retina[1][3][5][6]. RP1 is essential for the correct stacking of outer segment discs and the morphogenesis of rod and cone photoreceptors, maintaining retinal function and visual capacity[1][4][6]. Mutations in RP1 disrupt these processes, causing autosomal dominant and autosomal recessive forms of retinitis pigmentosa characterized by progressive degeneration of photoreceptor cells and visual impairment[2][4][6]. RP1 mutations are a significant cause of hereditary retinal dystrophy, and dysfunction of this protein links retinal degeneration to the wider class of microtubule-associated protein-related neurodegenerative disorders[6]. RP1 is not a traditional small molecule therapeutic target (such as a receptor or enzyme), nor are there known drugs that directly interact with it for clinical intervention[5][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Retinitis pigmentosa 1 protein (RP1).